JCAR 017

Drug Profile

JCAR 017

Alternative Names: 4-1BB-modified CAR CD8+ and CD4+ T lymphocyte therapy - Juno Therapeutics; anti-CD19-EGFRt-4-1BB-zeta modified CAR CD8+ and CD4+ T lymphocyte therapy - Juno Therapeutics; anti-CD19/EGFRt/4-1BB/zeta modified CAR CD8+ and CD4+ T lymphocyte therapy - Juno Therapeutics; JCAR017

Latest Information Update: 04 Jul 2017

Price : $50

At a glance

  • Originator Juno Therapeutics
  • Developer Juno Therapeutics; Seattle Children's Hospital
  • Class CAR-T cell therapies
  • Mechanism of Action CD19 antigen modulators; Cytotoxic T lymphocyte stimulants; Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Leukaemia
  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 17 Jun 2017 Juno Therapeutics plans a pivotal trial in patients with Diffuse large B cell lymphoma in the US in second half of 2017.
  • 17 Jun 2017 Efficacy and adverse events data from the phase I TRANSCEND trial in Diffuse large B-cell lymphoma released by Juno Therapeutics
  • 05 Jun 2017 Efficacy, adverse events and pharmacokinetics data from the phase I TRANSCEND trial in Diffuse large B cell lymphoma presented at the Annual Meeting of the American Society for Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top